vs
Avantor, Inc.（AVTR）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
Avantor, Inc.的季度营收约是瑞思迈的1.2倍（$1.7B vs $1.4B），瑞思迈净利率更高（27.6% vs 3.1%，领先24.4%），瑞思迈同比增速更快（11.0% vs -1.4%），瑞思迈自由现金流更多（$311.2M vs $117.2M），过去两年瑞思迈的营收复合增速更高（9.0% vs -0.5%）
Avantor是一家总部位于美国宾夕法尼亚州拉德诺的生物技术、化工及制药领域企业，前身为1904年成立的J.T. Baker，2010年正式更名，2019年在纽约证券交易所挂牌上市，股票代码为AVTR，为全球生命科学、医疗健康等行业客户提供核心产品与服务。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
AVTR vs RMD — 直观对比
营收规模更大
AVTR
是对方的1.2倍
$1.4B
营收增速更快
RMD
高出12.3%
-1.4%
净利率更高
RMD
高出24.4%
3.1%
自由现金流更多
RMD
多$194.0M
$117.2M
两年增速更快
RMD
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.4B |
| 净利润 | $52.4M | $392.6M |
| 毛利率 | 31.5% | 61.8% |
| 营业利润率 | 7.6% | 34.6% |
| 净利率 | 3.1% | 27.6% |
| 营收同比 | -1.4% | 11.0% |
| 净利润同比 | -89.5% | 13.9% |
| 每股收益（稀释后） | $0.08 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVTRRMD
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
净利润AVTRRMD
| Q4 25 | $52.4M | $392.6M | ||
| Q3 25 | $-711.8M | $348.5M | ||
| Q2 25 | $64.7M | $379.7M | ||
| Q1 25 | $64.5M | $365.0M | ||
| Q4 24 | $500.4M | $344.6M | ||
| Q3 24 | $57.8M | $311.4M | ||
| Q2 24 | $92.9M | $292.2M | ||
| Q1 24 | $60.4M | $300.5M |
毛利率AVTRRMD
| Q4 25 | 31.5% | 61.8% | ||
| Q3 25 | 32.4% | 61.5% | ||
| Q2 25 | 32.9% | 60.8% | ||
| Q1 25 | 33.8% | 59.3% | ||
| Q4 24 | 33.4% | 58.6% | ||
| Q3 24 | 32.9% | 58.6% | ||
| Q2 24 | 34.1% | 58.5% | ||
| Q1 24 | 34.0% | 57.9% |
营业利润率AVTRRMD
| Q4 25 | 7.6% | 34.6% | ||
| Q3 25 | -40.0% | 33.4% | ||
| Q2 25 | 7.7% | 33.7% | ||
| Q1 25 | 9.3% | 33.0% | ||
| Q4 24 | 37.8% | 32.5% | ||
| Q3 24 | 7.3% | 31.6% | ||
| Q2 24 | 10.3% | 31.2% | ||
| Q1 24 | 8.7% | 31.3% |
净利率AVTRRMD
| Q4 25 | 3.1% | 27.6% | ||
| Q3 25 | -43.8% | 26.1% | ||
| Q2 25 | 3.8% | 28.2% | ||
| Q1 25 | 4.1% | 28.3% | ||
| Q4 24 | 29.7% | 26.9% | ||
| Q3 24 | 3.4% | 25.4% | ||
| Q2 24 | 5.5% | 23.9% | ||
| Q1 24 | 3.6% | 25.1% |
每股收益（稀释后）AVTRRMD
| Q4 25 | $0.08 | $2.68 | ||
| Q3 25 | $-1.04 | $2.37 | ||
| Q2 25 | $0.09 | $2.58 | ||
| Q1 25 | $0.09 | $2.48 | ||
| Q4 24 | $0.73 | $2.34 | ||
| Q3 24 | $0.08 | $2.11 | ||
| Q2 24 | $0.14 | $1.97 | ||
| Q1 24 | $0.09 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $365.4M | $1.4B |
| 总债务越低越好 | $3.9B | $403.9M |
| 股东权益账面价值 | $5.6B | $6.3B |
| 总资产 | $11.8B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.71× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资AVTRRMD
| Q4 25 | $365.4M | $1.4B | ||
| Q3 25 | $251.9M | $1.4B | ||
| Q2 25 | $449.4M | $1.2B | ||
| Q1 25 | $315.7M | $932.7M | ||
| Q4 24 | $261.9M | $521.9M | ||
| Q3 24 | $285.3M | $426.4M | ||
| Q2 24 | $272.6M | $238.4M | ||
| Q1 24 | $234.9M | $237.9M |
总债务AVTRRMD
| Q4 25 | $3.9B | $403.9M | ||
| Q3 25 | $3.9B | $408.7M | ||
| Q2 25 | $4.2B | $658.4M | ||
| Q1 25 | $4.1B | $663.1M | ||
| Q4 24 | $4.1B | $662.9M | ||
| Q3 24 | $4.9B | $667.6M | ||
| Q2 24 | $5.1B | $697.3M | ||
| Q1 24 | $5.3B | $997.0M |
股东权益AVTRRMD
| Q4 25 | $5.6B | $6.3B | ||
| Q3 25 | $5.6B | $6.1B | ||
| Q2 25 | $6.3B | $6.0B | ||
| Q1 25 | $6.1B | $5.5B | ||
| Q4 24 | $6.0B | $5.3B | ||
| Q3 24 | $5.6B | $5.2B | ||
| Q2 24 | $5.4B | $4.9B | ||
| Q1 24 | $5.3B | $4.6B |
总资产AVTRRMD
| Q4 25 | $11.8B | $8.5B | ||
| Q3 25 | $11.7B | $8.3B | ||
| Q2 25 | $12.8B | $8.2B | ||
| Q1 25 | $12.3B | $7.6B | ||
| Q4 24 | $12.1B | $7.1B | ||
| Q3 24 | $12.8B | $7.2B | ||
| Q2 24 | $12.7B | $6.9B | ||
| Q1 24 | $12.8B | $6.8B |
负债/权益比AVTRRMD
| Q4 25 | 0.71× | 0.06× | ||
| Q3 25 | 0.69× | 0.07× | ||
| Q2 25 | 0.67× | 0.11× | ||
| Q1 25 | 0.67× | 0.12× | ||
| Q4 24 | 0.68× | 0.13× | ||
| Q3 24 | 0.89× | 0.13× | ||
| Q2 24 | 0.94× | 0.14× | ||
| Q1 24 | 1.00× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.7M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $117.2M | $311.2M |
| 自由现金流率自由现金流/营收 | 7.0% | 21.9% |
| 资本支出强度资本支出/营收 | 2.1% | 2.0% |
| 现金转化率经营现金流/净利润 | 2.91× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $495.0M | $1.8B |
8季度趋势，按日历期对齐
经营现金流AVTRRMD
| Q4 25 | $152.7M | $339.7M | ||
| Q3 25 | $207.4M | $457.3M | ||
| Q2 25 | $154.4M | $538.8M | ||
| Q1 25 | $109.3M | $578.7M | ||
| Q4 24 | $173.3M | $308.6M | ||
| Q3 24 | $244.8M | $325.5M | ||
| Q2 24 | $281.1M | $440.1M | ||
| Q1 24 | $141.6M | $402.0M |
自由现金流AVTRRMD
| Q4 25 | $117.2M | $311.2M | ||
| Q3 25 | $171.7M | $414.4M | ||
| Q2 25 | $124.8M | $508.2M | ||
| Q1 25 | $81.3M | $557.9M | ||
| Q4 24 | $145.8M | $288.0M | ||
| Q3 24 | $204.0M | $307.7M | ||
| Q2 24 | $235.3M | $415.2M | ||
| Q1 24 | $106.9M | $380.8M |
自由现金流率AVTRRMD
| Q4 25 | 7.0% | 21.9% | ||
| Q3 25 | 10.6% | 31.0% | ||
| Q2 25 | 7.4% | 37.7% | ||
| Q1 25 | 5.1% | 43.2% | ||
| Q4 24 | 8.6% | 22.5% | ||
| Q3 24 | 11.9% | 25.1% | ||
| Q2 24 | 13.8% | 33.9% | ||
| Q1 24 | 6.4% | 31.8% |
资本支出强度AVTRRMD
| Q4 25 | 2.1% | 2.0% | ||
| Q3 25 | 2.2% | 3.2% | ||
| Q2 25 | 1.8% | 2.3% | ||
| Q1 25 | 1.8% | 1.6% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 2.4% | 1.5% | ||
| Q2 24 | 2.7% | 2.0% | ||
| Q1 24 | 2.1% | 1.8% |
现金转化率AVTRRMD
| Q4 25 | 2.91× | 0.87× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | 2.39× | 1.42× | ||
| Q1 25 | 1.69× | 1.59× | ||
| Q4 24 | 0.35× | 0.90× | ||
| Q3 24 | 4.24× | 1.05× | ||
| Q2 24 | 3.03× | 1.51× | ||
| Q1 24 | 2.34× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
